Nemaura Medical Inc. (NASDAQ:NMRD – Get Rating) – Research analysts at HC Wainwright cut their Q3 2023 earnings per share (EPS) estimates for shares of Nemaura Medical in a research report issued to clients and investors on Monday, November 21st. HC Wainwright analyst Y. Chen now forecasts that the company will post earnings of ($0.18) per share for the quarter, down from their prior estimate of ($0.16). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Nemaura Medical’s current full-year earnings is ($0.64) per share. HC Wainwright also issued estimates for Nemaura Medical’s Q4 2023 earnings at ($0.17) EPS, FY2023 earnings at ($0.69) EPS, Q1 2024 earnings at ($0.15) EPS, Q2 2024 earnings at ($0.14) EPS, Q3 2024 earnings at ($0.13) EPS, Q4 2024 earnings at ($0.12) EPS and FY2024 earnings at ($0.55) EPS.
Nemaura Medical Price Performance
NMRD stock opened at $2.00 on Thursday. Nemaura Medical has a 1-year low of $1.50 and a 1-year high of $5.94. The business’s 50 day simple moving average is $2.19 and its 200 day simple moving average is $2.29.
Institutional Inflows and Outflows
About Nemaura Medical
Nemaura Medical Inc, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. It provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs.
- Get a free copy of the StockNews.com research report on Nemaura Medical (NMRD)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for Nemaura Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nemaura Medical and related companies with MarketBeat.com's FREE daily email newsletter.